Third Military Medical University
Welcome,         Profile    Billing    Logout  
 28 Trials 
15 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mao, Qing
NCT04683406: A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A

Completed
3
750
RoW
ZSP1273 600 mg, Placebo to Oseltamivir, Oseltamivir(oral), Placebo to ZSP1273
Guangdong Raynovent Biotech Co., Ltd
Influenza A
04/23
05/23
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
NCT04449588 / 2020-001671-32: Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS

Terminated
2/3
369
Europe, RoW
BDB-001 Injection, Conventional treatment
Staidson (Beijing) Biopharmaceuticals Co., Ltd, Beijing Defengrui Biotechnology Co. Ltd
COVID-19 Pneumonia
03/24
03/24
NCT04426968: A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis B

Completed
2
96
RoW
Hepalatide 2.1mg, L47, Hepalatide 4.2mg, Hepalatide 6.3mg, placebo 2.1mg, placebo 4.2mg, placebo 6.3mg, Pegylated Interferon, Pegasys
Shanghai HEP Pharmaceutical Co., Ltd.
Hepatitis B, Chronic
11/23
11/23
NCT06150014: A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B

Active, not recruiting
1/2
88
RoW
Placebo, TQA3605 tablets, Entecavir dispersible tablets, Tenofovir disoproxil fumarate tablet, Tenofovir alafenamide fumarate tablet
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Hepatitis b
12/25
09/26
NCT06452693: A Clinical Study to Evaluate the Efficacy of TQA3038 Injection in Patients With Chronic Hepatitis B

Not yet recruiting
1/2
162
RoW
TQA3038 injection/placebo, Nucleotide drugs Control group
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hepatitis B, Chronic
09/26
09/26
NCT06363162: Evaluate the Effectiveness and Safety of Raman IVD Analyzer in the Molecular Diagnosis of Gliomas During Surgery

Recruiting
N/A
200
RoW
Immunohistochemistry or genetic test, Raman analyzer diagnosis
Beijing Tiantan Hospital, West China Hospital, The First Affiliated Hospital of Zhengzhou University, Capital Medical University, Jiangsu Raman Medical Equipment Co., Ltd.
Glioma
06/25
12/25
Zhang, Leida
ENREACH-PDAC-01, NCT05149326: KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.

Active, not recruiting
3
408
RoW
KN046, placebo
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Advanced Pancreatic Ductal Adenocarcinoma
04/24
08/24
NCT06310590: Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma

Recruiting
1
40
RoW
NRT6003 Injection, Yttrium-90 carbon microspheres
Chengdu New Radiomedicine Technology Co. LTD.
Unresectable Hepatocellular Carcinoma
10/25
10/25
Wang, Bin S
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)

Active, not recruiting
4
8250
RoW
Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy
Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases
04/25
04/25
ACHIEVE, NCT04808752: Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases

Active, not recruiting
2
63
RoW
Almonertinib, Investigational Product
Zhejiang Cancer Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Lung Cancer
06/24
07/24
NCT06006689: Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis)

Recruiting
2
228
RoW
Qishen Yiqi Dripping Pills placebo 3 bags, Placebo group, Low dose Qishen Yiqi Dripping Pills 3 bags, Low dose group, High dose Qishen Yiqi Dripping Pills 3 bags, High dose group
Tasly Pharmaceutical Group Co., Ltd
Diabetic Kidney Disease
09/25
09/25
NCT05703191: A Real-world Study of Nitric Oxide Generator and Delivery System

Recruiting
N/A
10
RoW
Nitric Oxide Generator and Delivery System
Novlead Inc.
Pulmonary Hypertension of Newborn
03/25
05/25
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System

Not yet recruiting
N/A
2150
RoW
Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy
Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Heart Disease
01/26
01/28
Jin, Jun
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)

Active, not recruiting
4
8250
RoW
Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy
Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases
04/25
04/25
Wei, Yanling
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mao, Qing
NCT04683406: A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A

Completed
3
750
RoW
ZSP1273 600 mg, Placebo to Oseltamivir, Oseltamivir(oral), Placebo to ZSP1273
Guangdong Raynovent Biotech Co., Ltd
Influenza A
04/23
05/23
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
NCT04449588 / 2020-001671-32: Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS

Terminated
2/3
369
Europe, RoW
BDB-001 Injection, Conventional treatment
Staidson (Beijing) Biopharmaceuticals Co., Ltd, Beijing Defengrui Biotechnology Co. Ltd
COVID-19 Pneumonia
03/24
03/24
NCT04426968: A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis B

Completed
2
96
RoW
Hepalatide 2.1mg, L47, Hepalatide 4.2mg, Hepalatide 6.3mg, placebo 2.1mg, placebo 4.2mg, placebo 6.3mg, Pegylated Interferon, Pegasys
Shanghai HEP Pharmaceutical Co., Ltd.
Hepatitis B, Chronic
11/23
11/23
NCT06150014: A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B

Active, not recruiting
1/2
88
RoW
Placebo, TQA3605 tablets, Entecavir dispersible tablets, Tenofovir disoproxil fumarate tablet, Tenofovir alafenamide fumarate tablet
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Hepatitis b
12/25
09/26
NCT06452693: A Clinical Study to Evaluate the Efficacy of TQA3038 Injection in Patients With Chronic Hepatitis B

Not yet recruiting
1/2
162
RoW
TQA3038 injection/placebo, Nucleotide drugs Control group
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hepatitis B, Chronic
09/26
09/26
NCT06363162: Evaluate the Effectiveness and Safety of Raman IVD Analyzer in the Molecular Diagnosis of Gliomas During Surgery

Recruiting
N/A
200
RoW
Immunohistochemistry or genetic test, Raman analyzer diagnosis
Beijing Tiantan Hospital, West China Hospital, The First Affiliated Hospital of Zhengzhou University, Capital Medical University, Jiangsu Raman Medical Equipment Co., Ltd.
Glioma
06/25
12/25
Zhang, Leida
ENREACH-PDAC-01, NCT05149326: KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.

Active, not recruiting
3
408
RoW
KN046, placebo
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Advanced Pancreatic Ductal Adenocarcinoma
04/24
08/24
NCT06310590: Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma

Recruiting
1
40
RoW
NRT6003 Injection, Yttrium-90 carbon microspheres
Chengdu New Radiomedicine Technology Co. LTD.
Unresectable Hepatocellular Carcinoma
10/25
10/25
Wang, Bin S
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)

Active, not recruiting
4
8250
RoW
Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy
Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases
04/25
04/25
ACHIEVE, NCT04808752: Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases

Active, not recruiting
2
63
RoW
Almonertinib, Investigational Product
Zhejiang Cancer Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Lung Cancer
06/24
07/24
NCT06006689: Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis)

Recruiting
2
228
RoW
Qishen Yiqi Dripping Pills placebo 3 bags, Placebo group, Low dose Qishen Yiqi Dripping Pills 3 bags, Low dose group, High dose Qishen Yiqi Dripping Pills 3 bags, High dose group
Tasly Pharmaceutical Group Co., Ltd
Diabetic Kidney Disease
09/25
09/25
NCT05703191: A Real-world Study of Nitric Oxide Generator and Delivery System

Recruiting
N/A
10
RoW
Nitric Oxide Generator and Delivery System
Novlead Inc.
Pulmonary Hypertension of Newborn
03/25
05/25
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System

Not yet recruiting
N/A
2150
RoW
Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy
Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Heart Disease
01/26
01/28
Jin, Jun
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)

Active, not recruiting
4
8250
RoW
Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy
Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases
04/25
04/25
Wei, Yanling
No trials found

Download Options